BACKGROUND: Duration of untreated psychosis (DUP) has been significantly associated with poor clinical and social outcomes in First Episode Psychosis (FEP) patients, but an association with cognitive outcomes has not been clearly established. METHOD: Seventy-seven consecutively admitted, drug-naïve patients with FEP were assessed at baseline and at 1month and 6months. Underlying dimensions of DUP (general prodrome and positive, negative and disorganisation symptoms) were assessed using the Symptom Onset in Schizophrenia (SOS) inventory (Perkins et al., 2000). To assess the effect of DUP on the neuropsychological status of the patients, a linear mixed-effect model was fitted to each neuropsychological dimension. These models included a dichotomised version of DUP (short versus long duration) as a fixed effect, several adjusting variables to account for patient differences, and a random effect to incorporate the longitudinal structure of the data. RESULTS:Patients with a short duration of untreated negative symptoms (DUNS) or a short duration of untreated positive symptoms (DUPS) outperformed patients with a long duration of untreated symptoms onmemory tasks and a pre-attentional visual task but not on measures of verbal fluency, attention, reaction time, visual processing and executive functions. CONCLUSIONS: This study provides additional support for an early intervention to shorten DUP to facilitate a better outcome in memory and attentional domains of FEP patients.
RCT Entities:
BACKGROUND: Duration of untreated psychosis (DUP) has been significantly associated with poor clinical and social outcomes in First Episode Psychosis (FEP) patients, but an association with cognitive outcomes has not been clearly established. METHOD: Seventy-seven consecutively admitted, drug-naïve patients with FEP were assessed at baseline and at 1month and 6months. Underlying dimensions of DUP (general prodrome and positive, negative and disorganisation symptoms) were assessed using the Symptom Onset in Schizophrenia (SOS) inventory (Perkins et al., 2000). To assess the effect of DUP on the neuropsychological status of the patients, a linear mixed-effect model was fitted to each neuropsychological dimension. These models included a dichotomised version of DUP (short versus long duration) as a fixed effect, several adjusting variables to account for patient differences, and a random effect to incorporate the longitudinal structure of the data. RESULTS:Patients with a short duration of untreated negative symptoms (DUNS) or a short duration of untreated positive symptoms (DUPS) outperformed patients with a long duration of untreated symptoms on memory tasks and a pre-attentional visual task but not on measures of verbal fluency, attention, reaction time, visual processing and executive functions. CONCLUSIONS: This study provides additional support for an early intervention to shorten DUP to facilitate a better outcome in memory and attentional domains of FEP patients.
Authors: Manuel J Cuesta; Ana M Sánchez-Torres; Elena García de Jalón; Maria S Campos; Berta Ibáñez; Lucía Moreno-Izco; Víctor Peralta Journal: Schizophr Bull Date: 2013-09-26 Impact factor: 9.306
Authors: Beth Broussard; Mary E Kelley; Claire Ramsay Wan; Sarah L Cristofaro; Anthony Crisafio; Patrick J Haggard; Neely L Myers; Thomas Reed; Michael T Compton Journal: Schizophr Res Date: 2013-06-06 Impact factor: 4.939
Authors: Ricardo E Carrión; Docia Demmin; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Todd Lencz; Christoph U Correll; Barbara A Cornblatt Journal: J Psychiatr Res Date: 2016-06-26 Impact factor: 4.791
Authors: Cherise Rosen; Michele Tufano; Clara S Humpston; Kayla A Chase; Nev Jones; Amy C Abramowitz; Ann Franco Chakkalakal; Rajiv P Sharma Journal: Front Psychiatry Date: 2021-05-10 Impact factor: 4.157
Authors: Itziar Montalvo; Alfonso Gutiérrez-Zotes; Marta Creus; Rosa Monseny; Laura Ortega; Joan Franch; Stephen M Lawrie; Rebecca M Reynolds; Elisabet Vilella; Javier Labad Journal: PLoS One Date: 2014-02-24 Impact factor: 3.240
Authors: Konstantinos N Fountoulakis; Elena Dragioti; Antonis T Theofilidis; Tobias Wikilund; Xenofon Atmatzidis; Ioannis Nimatoudis; Erik Thys; Martien Wampers; Luchezar Hranov; Trayana Hristova; Daniil Aptalidis; Roumen Milev; Felicia Iftene; Filip Spaniel; Pavel Knytl; Petra Furstova; Tiina From; Henry Karlsson; Maija Walta; Raimo K R Salokangas; Jean-Michel Azorin; Justine Bouniard; Julie Montant; Georg Juckel; Ida S Haussleiter; Athanasios Douzenis; Ioannis Michopoulos; Panagiotis Ferentinos; Nikolaos Smyrnis; Leonidas Mantonakis; Zsófia Nemes; Xenia Gonda; Dora Vajda; Anita Juhasz; Amresh Shrivastava; John Waddington; Maurizio Pompili; Anna Comparelli; Valentina Corigliano; Elmars Rancans; Alvydas Navickas; Jan Hilbig; Laurynas Bukelskis; Lidija Injac Stevovic; Sanja Vodopic; Oluyomi Esan; Oluremi Oladele; Christopher Osunbote; Janusz Κ Rybakowski; Pawel Wojciak; Klaudia Domowicz; Maria Luisa Figueira; Ludgero Linhares; Joana Crawford; Anca-Livia Panfil; Daria Smirnova; Olga Izmailova; Dusica Lecic-Tosevski; Henk Temmingh; Fleur Howells; Julio Bobes; Maria Paz Garcia-Portilla; Leticia García-Alvarez; Gamze Erzin; Hasan Karadağ; Avinash De Sousa; Anuja Bendre; Cyril Hoschl; Cristina Bredicean; Ion Papava; Olivera Vukovic; Bojana Pejuskovic; Vincent Russell; Loukas Athanasiadis; Anastasia Konsta; Dan Stein; Michael Berk; Olivia Dean; Rajiv Tandon; Siegfried Kasper; Marc De Hert Journal: Int J Neuropsychopharmacol Date: 2019-11-01 Impact factor: 5.176